Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S.
Yamaguchi H, et al. Among authors: nakamura y.
Cancer Chemother Pharmacol. 2011 Feb;67(2):331-8. doi: 10.1007/s00280-010-1325-x. Epub 2010 Apr 17.
Cancer Chemother Pharmacol. 2011.
PMID: 20401612
Clinical Trial.